Mechanisms underlying the inhibitory effects induced by pituitary adenylate cyclase-activating peptide in mouse ileum

Eur J Pharmacol. 2005 Oct 3;521(1-3):133-8. doi: 10.1016/j.ejphar.2005.08.027. Epub 2005 Sep 23.

Abstract

The aim of this study was to investigate the signal transduction mechanisms underlying the inhibitory effect induced by pituitary adenylate cyclase activating peptide (PACAP-27) on the spontaneous contractile activity of longitudinal muscle of mouse ileum. Mechanical activity of ileal segments was recorded isometrically in vitro. PACAP-27 produced apamin-sensitive reduction of the amplitude of the spontaneous contractions. 9-(Tetrahydro-2-furanyl)-9H-purin-6-amine (SQ 22,536), adenylate cyclase inhibitor, or genistein and tyrphostin 25, tyrosine kinase inhibitors, had negligible effects on PACAP-27-induced inhibition. PACAP-27 effects were significantly inhibited by U-73122, phopholipase C (PLC) inhibitor, by 2-aminoethoxy-diphenylborate (2-APB), permeable blocker of inositol 1,4,5-triphosphate (IP3) receptors and by depletion of Ca2+ stores with cyclopiazonic acid or thapsigargin. Ryanodine did not reduce PACAP-27-inhibitory responses. We suggest that, in mouse ileum, the inhibitory responses to PACAP-27 involve stimulation of PLC, increased production of IP3 and localised Ca2+ release from intracellular stores, which could provide the opening of apamin-sensitive Ca2+-dependent K+ channels.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenine / analogs & derivatives
  • Adenine / pharmacology
  • Adenylyl Cyclase Inhibitors
  • Animals
  • Apamin / pharmacology
  • Boron Compounds / pharmacology
  • Calcium / metabolism
  • Calcium-Transporting ATPases / antagonists & inhibitors
  • Dose-Response Relationship, Drug
  • Enzyme Inhibitors / pharmacology
  • Estrenes / pharmacology
  • Genistein / pharmacology
  • Ileum / drug effects*
  • Ileum / physiology
  • In Vitro Techniques
  • Indoles / pharmacology
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Muscle Contraction / drug effects*
  • Muscle, Smooth / drug effects
  • Muscle, Smooth / metabolism
  • Muscle, Smooth / physiology
  • NG-Nitroarginine Methyl Ester / pharmacology
  • Nitric Oxide Synthase / antagonists & inhibitors
  • Phosphodiesterase Inhibitors / pharmacology
  • Pituitary Adenylate Cyclase-Activating Polypeptide / pharmacology*
  • Protein-Tyrosine Kinases / antagonists & inhibitors
  • Pyrrolidinones / pharmacology
  • Ryanodine / pharmacology
  • Thapsigargin / pharmacology
  • Tyrphostins / pharmacology
  • Vasodilator Agents / pharmacology

Substances

  • Adenylyl Cyclase Inhibitors
  • Boron Compounds
  • Enzyme Inhibitors
  • Estrenes
  • Indoles
  • Phosphodiesterase Inhibitors
  • Pituitary Adenylate Cyclase-Activating Polypeptide
  • Pyrrolidinones
  • Tyrphostins
  • Vasodilator Agents
  • 1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione
  • tyrphostin 25
  • Ryanodine
  • 9-(tetrahydro-2-furyl)-adenine
  • Apamin
  • Thapsigargin
  • Genistein
  • 2-aminoethoxydiphenyl borate
  • Nitric Oxide Synthase
  • Protein-Tyrosine Kinases
  • Calcium-Transporting ATPases
  • Adenine
  • Calcium
  • NG-Nitroarginine Methyl Ester
  • cyclopiazonic acid